AR058696A1 - Sal de sulfato de hidrogeno del acido 6-(4-bromo-2-cloro-fenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico. - Google Patents

Sal de sulfato de hidrogeno del acido 6-(4-bromo-2-cloro-fenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico.

Info

Publication number
AR058696A1
AR058696A1 ARP060105662A ARP060105662A AR058696A1 AR 058696 A1 AR058696 A1 AR 058696A1 AR P060105662 A ARP060105662 A AR P060105662A AR P060105662 A ARP060105662 A AR P060105662A AR 058696 A1 AR058696 A1 AR 058696A1
Authority
AR
Argentina
Prior art keywords
hydrogen sulfate
sulfate salt
carboxilico
benzoimidazol
phenylamine
Prior art date
Application number
ARP060105662A
Other languages
English (en)
Inventor
John Demattei
Chuang-Tsung-Hsun
Richard Anthony Storey
Gorkhn Sharma-Singh
Paul Alfred Dickinson
Mohammed Pervez
Cristopher Jhon Squire
James Gair Ford
Ronald John Roberts
Original Assignee
Array Biopharma Inc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218759&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058696(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc, Astrazeneca Ab filed Critical Array Biopharma Inc
Publication of AR058696A1 publication Critical patent/AR058696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Abstract

La presente se relaciona con una sal de sulfato de hidrogeno del Compuesto (1) y solvatos, formas cristalinas y formas amorfas de ella, y con procesos para su preparacion. Util para tratar enfermedad proliferativa. Inhibidor de MEK.
ARP060105662A 2005-12-21 2006-12-20 Sal de sulfato de hidrogeno del acido 6-(4-bromo-2-cloro-fenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico. AR058696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75278105P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
AR058696A1 true AR058696A1 (es) 2008-02-20

Family

ID=38218759

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105662A AR058696A1 (es) 2005-12-21 2006-12-20 Sal de sulfato de hidrogeno del acido 6-(4-bromo-2-cloro-fenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico.

Country Status (31)

Country Link
US (4) US20100016393A1 (es)
EP (1) EP1968948B1 (es)
JP (1) JP5127723B2 (es)
KR (1) KR101361460B1 (es)
CN (2) CN101360718B (es)
AR (1) AR058696A1 (es)
AU (1) AU2006330759B2 (es)
BR (1) BRPI0620091A2 (es)
CA (1) CA2634149C (es)
CY (1) CY1114303T1 (es)
DK (1) DK1968948T3 (es)
EC (1) ECSP088597A (es)
ES (1) ES2421746T3 (es)
FR (1) FR21C1051I2 (es)
HK (1) HK1124043A1 (es)
HR (1) HRP20130663T1 (es)
HU (1) HUS2100046I1 (es)
IL (1) IL192224A (es)
LT (1) LTC1968948I2 (es)
MX (1) MX2008008298A (es)
MY (1) MY157733A (es)
NL (1) NL301139I2 (es)
NZ (1) NZ569792A (es)
PL (1) PL1968948T3 (es)
PT (1) PT1968948E (es)
RS (1) RS52843B (es)
SI (1) SI1968948T1 (es)
TW (1) TWI405756B (es)
UA (1) UA93531C2 (es)
WO (1) WO2007076245A2 (es)
ZA (1) ZA200805705B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG148857A1 (en) 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US20100004247A1 (en) * 2007-12-12 2010-01-07 Astrazeneca Ab Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
SA109300195B1 (ar) * 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US9220775B2 (en) 2011-11-23 2015-12-29 Medimmune Llc Binding molecules specific for HER3 and uses thereof
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
LT3702351T (lt) 2012-10-19 2024-01-10 Array Biopharma, Inc. Kompozicijos, apimančios mek inhibitorių
BR112015020787B1 (pt) 2013-03-06 2022-12-06 Astrazeneca Ab Compostos 4-(substituído-anilino)-6-o-(substituídopiperizina-carbonil)quinazolínicos, seus sais, composição farmacêutica, uso e combinação
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
CN105566327A (zh) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
EP3355923B1 (en) 2015-10-01 2022-02-23 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma
MX2018004309A (es) * 2015-10-06 2018-05-22 Redhill Biopharma Ltd Terapias combinadas para tratar el cancer.
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
CN109438362B (zh) * 2017-11-14 2020-07-21 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
CR20210211A (es) * 2018-10-31 2021-05-25 Vernalis R&D Ltd Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contienen la misma
US20220405506A1 (en) * 2021-06-22 2022-12-22 Intrinsic Innovation Llc Systems and methods for a vision guided end effector
WO2023238000A1 (en) * 2022-06-06 2023-12-14 Glenmark Life Sciences Limited Process for preparation of selumetinib and salts thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
HUP9903014A3 (en) 1996-07-18 2000-08-28 Pfizer Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
US6153609A (en) 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2277100C (en) 1997-01-06 2005-11-22 Pfizer Inc. Cyclic sulfone derivatives
TR199901849T2 (xx) 1997-02-03 2000-02-21 Pfizer Products Inc. Arils�lfonilamino hidroksamik asit t�revleri.
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
SG148857A1 (en) * 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
MXPA06002657A (es) 2003-09-09 2006-06-05 Fumapharm Ag Uso de derivados de acido fumarico para el tratamiento de insuficiencia cardiaca y asma.
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
SA109300195B1 (ar) * 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان

Also Published As

Publication number Publication date
FR21C1051I2 (fr) 2023-02-17
HK1124043A1 (en) 2009-07-03
US9156795B2 (en) 2015-10-13
ECSP088597A (es) 2008-08-29
SI1968948T1 (sl) 2013-08-30
US20120253049A1 (en) 2012-10-04
RS52843B (en) 2013-12-31
MY157733A (en) 2016-07-15
FR21C1051I1 (fr) 2021-12-24
LTPA2021530I1 (es) 2021-12-27
NL301139I2 (nl) 2022-02-22
JP2009521487A (ja) 2009-06-04
CN101360718A (zh) 2009-02-04
CA2634149C (en) 2013-08-13
DK1968948T3 (da) 2013-08-26
ES2421746T3 (es) 2013-09-05
NZ569792A (en) 2011-01-28
US20160024018A1 (en) 2016-01-28
NL301139I1 (es) 2021-11-03
CA2634149A1 (en) 2007-07-05
TW200800915A (en) 2008-01-01
ZA200805705B (en) 2012-09-26
EP1968948A4 (en) 2010-12-15
JP5127723B2 (ja) 2013-01-23
WO2007076245A3 (en) 2008-01-24
CN101360718B (zh) 2012-01-11
AU2006330759B2 (en) 2012-12-06
EP1968948A2 (en) 2008-09-17
EP1968948B1 (en) 2013-05-22
KR101361460B1 (ko) 2014-02-10
PL1968948T3 (pl) 2013-10-31
HRP20130663T1 (en) 2013-08-31
AU2006330759A1 (en) 2007-07-05
MX2008008298A (es) 2008-09-24
WO2007076245A2 (en) 2007-07-05
KR20080080200A (ko) 2008-09-02
UA93531C2 (en) 2011-02-25
IL192224A (en) 2014-08-31
LTC1968948I2 (es) 2023-07-10
IL192224A0 (en) 2009-02-11
HUS2100046I1 (hu) 2021-11-29
CN102329270A (zh) 2012-01-25
CY1114303T1 (el) 2016-08-31
US20100016393A1 (en) 2010-01-21
PT1968948E (pt) 2013-07-25
US20140221443A1 (en) 2014-08-07
BRPI0620091A2 (pt) 2011-11-01
TWI405756B (zh) 2013-08-21
US9562017B2 (en) 2017-02-07

Similar Documents

Publication Publication Date Title
AR058696A1 (es) Sal de sulfato de hidrogeno del acido 6-(4-bromo-2-cloro-fenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico.
ECSP12012026A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
AR098260A2 (es) Polimorfo cristalino de una sal de bisulfato de un antagonista del receptor de trombina, proceso para su preparación, composición y forma purificada
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
NO20065321L (no) Fremgangsmate for fremstilling av clopidogrelhydrogensulfat polymorf for I
MY175373A (en) Crystal form of phenylamino pyrimidine derivatives
NZ591498A (en) Novel phenylamino isonicotinamide compounds
AR052681A1 (es) Formas cristalinas de 2-(3-fluoro-4 hidroxifenil ) -7 -vinil-1,3- benzoxazol -5-ol
UY31502A1 (es) Proceso mejorado para sintetizar 5-cyclopentyl-5-11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ol usando tmeda
NI201000225A (es) Composición y proceso - 356.
CO6241155A2 (es) [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo
RS54354B1 (en) CORTEXOLONE-17ALFA-PROPIONATE IN CRYSTAL FORM I
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
DOP2021000074A (es) Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contiene la misma
BR112015026909A2 (pt) processo para a preparação de 1, 2-benzisotiazolin-3-onas
BR112017007953A2 (pt) forma cristalina de um bissulfato inibidor de jak quinase e método de preparação desse
CO6311068A2 (es) Composiciones farmacéuticas que comprenden una sal, hidrógeno sulfato del ácido 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-carboxilico y un vehiculo matriz
NI200700175A (es) Procesos para la preparación de alcoholes de aminoetoxibencilo
EA200701256A1 (ru) Способ получения высокочистых мелоксикама и калиевой соли мелоксикама
AR111906A1 (es) Formas cristalinas de 5-bromo-2,6-di(1h-pirazol-1-il)pirimidin-4-amina y sales
IL188109A0 (en) Chloro-substituted guanidines
CR9174A (es) Composiciones y procesos para preparar 13-desoxi antraciclinas
AR068349A1 (es) Polimorfos de agonistas de prostaglandinas y procedimientos para fabricar los mismos
CY1117185T1 (el) Κρυσταλλικες μορφες της 3-(2,6-διχλωρο-3,5-διμεθοξυ-φαινυλ)-1-{6-[4-(4-αιθυλ-πιπεραζιν-1-υλ)-φαινυλαμινο]-πυριμιδιν-4-υλ}-1-μεθυλ-ουριας και αλατα αυτων
ATE493995T1 (de) Magmatithaltige topische zusammensetzung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FC Refusal